Last reviewed · How we verify
PemCarbo
PemCarbo is a combination chemotherapy regimen pairing pemetrexed (an antifolate antimetabolite) with carboplatin (a platinum-based alkylating agent) to inhibit DNA synthesis and repair.
PemCarbo is a combination chemotherapy regimen pairing pemetrexed (an antifolate antimetabolite) with carboplatin (a platinum-based alkylating agent) to inhibit DNA synthesis and repair. Used for Non-small cell lung cancer (likely first-line or maintenance), Malignant pleural mesothelioma (possible indication).
At a glance
| Generic name | PemCarbo |
|---|---|
| Also known as | Alimta: brand name of Pemetrexed |
| Sponsor | Asan Medical Center |
| Drug class | Chemotherapy combination (antifolate + platinum agent) |
| Target | Thymidylate synthase, dihydrofolate reductase (pemetrexed); DNA (carboplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Pemetrexed inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, while carboplatin forms DNA cross-links that prevent replication and transcription. Together, these agents provide synergistic cytotoxic activity against rapidly dividing cancer cells. This combination is commonly used in lung cancer and mesothelioma treatment.
Approved indications
- Non-small cell lung cancer (likely first-line or maintenance)
- Malignant pleural mesothelioma (possible indication)
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Fatigue
- Nephrotoxicity
- Peripheral neuropathy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PemCarbo CI brief — competitive landscape report
- PemCarbo updates RSS · CI watch RSS
- Asan Medical Center portfolio CI